These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

118 related articles for article (PubMed ID: 15057032)

  • 1. Pathological laughter as an obsessive-compulsive phenomenon.
    Mendhekar DN
    Psychopathology; 2004; 37(2):81-3. PubMed ID: 15057032
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of tryptophan depletion on selective serotonin reuptake inhibitor-remitted patients with obsessive compulsive disorder.
    Hood SD; Broyd A; Robinson H; Lee J; Hudaib AR; Hince DA
    J Psychopharmacol; 2017 Dec; 31(12):1615-1623. PubMed ID: 29095069
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Use of factor-analyzed symptom dimensions to predict outcome with serotonin reuptake inhibitors and placebo in the treatment of obsessive-compulsive disorder.
    Mataix-Cols D; Rauch SL; Manzo PA; Jenike MA; Baer L
    Am J Psychiatry; 1999 Sep; 156(9):1409-16. PubMed ID: 10484953
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Response of symptom dimensions in obsessive-compulsive disorder to treatment with citalopram or placebo.
    Stein DJ; Andersen EW; Overo KF
    Braz J Psychiatry; 2007 Dec; 29(4):303-7. PubMed ID: 18200396
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Hoarding in obsessive-compulsive disorder and related disorders: a preliminary report of 15 cases.
    Seedat S; Stein DJ
    Psychiatry Clin Neurosci; 2002 Feb; 56(1):17-23. PubMed ID: 11929567
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shared obsessive-compulsive disorder: broadening the concept of shared psychotic disorder.
    Mergui J; Jaworowski S; Greenberg D; Lerner V
    Aust N Z J Psychiatry; 2010 Sep; 44(9):859-62. PubMed ID: 20815674
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Olanzapine addition in obsessive-compulsive disorder refractory to selective serotonin reuptake inhibitors: an open-label case series.
    Weiss EL; Potenza MN; McDougle CJ; Epperson CN
    J Clin Psychiatry; 1999 Aug; 60(8):524-7. PubMed ID: 10485634
    [TBL] [Abstract][Full Text] [Related]  

  • 8. When Obsessive-Compulsive Disorder Mimics Schizophrenia.
    Duarte-Mangas M; Bravo L; Matos-Pires A
    J Nerv Ment Dis; 2020 Dec; 208(12):997-999. PubMed ID: 33252515
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Case series: Adderall augmentation of serotonin reuptake inhibitors in childhood-onset obsessive compulsive disorder.
    Owley T; Owley S; Leventhal B; Cook EH
    J Child Adolesc Psychopharmacol; 2002; 12(2):165-71. PubMed ID: 12188985
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Kinematical analysis of emotionally induced facial expressions in patients with obsessive-compulsive disorder.
    Mergl R; Vogel M; Mavrogiorgou P; Göbel C; Zaudig M; Hegerl U; Juckel G
    Psychol Med; 2003 Nov; 33(8):1453-62. PubMed ID: 14672254
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Psychopharmacology of pediatric obsessive-compulsive disorder: three case reports.
    Oner O; Oner P
    J Psychopharmacol; 2008 Sep; 22(7):809-11. PubMed ID: 18308783
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Topiramate plus paroxetine in treatment-resistant obsessive-compulsive disorder.
    Hollander E; Dell'Osso B
    Int Clin Psychopharmacol; 2006 May; 21(3):189-91. PubMed ID: 16528143
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Selective serotonin reuptake inhibitors, and serotonin and norepinephrine reuptake inhibitors for anxiety, obsessive-compulsive, and stress disorders: A 3-level network meta-analysis.
    Gosmann NP; Costa MA; Jaeger MB; Motta LS; Frozi J; Spanemberg L; Manfro GG; Cuijpers P; Pine DS; Salum GA
    PLoS Med; 2021 Jun; 18(6):e1003664. PubMed ID: 34111122
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Obsessive-compulsive spectrum disorders: effective treatment with paroxetine.
    Ravindran AV; Lapierre YD; Anisman H
    Can J Psychiatry; 1999 Oct; 44(8):805-7. PubMed ID: 10566112
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A longitudinal event-related potential study of selective serotonin reuptake inhibitor therapy in treatment-naïve pediatric obsessive compulsive disorder patients.
    Yamamuro K; Ota T; Iida J; Kishimoto N; Nakanishi Y; Matsuura H; Uratani M; Okazaki K; Kishimoto T
    Psychiatry Res; 2016 Nov; 245():217-223. PubMed ID: 27552672
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Selective serotonin reuptake inhibitors in treatment of compulsive symptoms within the scope of schizophrenia].
    Scholl HP; Kasper S; Danos P; Höflich G; Möller HJ
    Nervenarzt; 1994 Jul; 65(7):478-81. PubMed ID: 7800092
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of selective serotonin reuptake inhibitors on thought-action fusion, metacognitions, and thought suppression in obsessive-compulsive disorder.
    Besiroglu L; Çetinkaya N; Selvi Y; Atli A
    Compr Psychiatry; 2011; 52(5):556-61. PubMed ID: 21109243
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The first Japanese pediatric case of obsessive-compulsive disorder who responded to a selective serotonin re-uptake inhibitor.
    Furusho J; Kubagawa T; Saitoh N; Matsuzaki K; Yamakawa H; Iikura Y
    Pediatr Int; 2000 Aug; 42(4):451-2. PubMed ID: 10986886
    [No Abstract]   [Full Text] [Related]  

  • 19. Obsessive-compulsive disorder in Tourette syndrome.
    Goodman WK; Storch EA; Geffken GR; Murphy TK
    J Child Neurol; 2006 Aug; 21(8):704-14. PubMed ID: 16970872
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Effectiveness of fluoxetine on various subtypes of obsessive-compulsive disorder.
    Farnam A; Goreishizadeh MA; Farhang S
    Arch Iran Med; 2008 Sep; 11(5):522-5. PubMed ID: 18759519
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.